Poster Abstracts
| العنوان: | Poster Abstracts |
|---|---|
| المؤلفون: | Caner Ercan, William Schwartz, Jonathan Swann, Andrew Shenchi Kao, Mohamed A. Mohamed Ali, Kirsten Lykkegaard, Daniel Ketelhuth, Joana Espírito Santo, Saleh Alqahtani, Anas Elgenidy, Shiqi Zhong, Harpreet Kaur, Debashis Sarker, Raja Ganesan, Jun Porto, Munira Jahan, Raad Rahmat, Kelly Yang |
| المصدر: | Hepatology. 74:157-1288 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Hepatology, Coronavirus disease 2019 (COVID-19), Age groups, business.industry, Maximum likelihood, Pandemic, Mixed effects, Hcv treatment, Medicine, business, Random intercept, Demography, HCV Antibody |
| الوصف: | Background: Recent reports indicated declines in HCV testing during the first half of 2020 in the United States due to COVID-19, but it is unclear whether a longer-term impact on HCV testing and treatment initiations was observed. The objective of this study was to investigate the nationwide impact of the pandemic on HCV testing and treatment in the United States through the end of 2020. Methods: We obtained monthly state-level volumes of HCV Ab testing and HCV treatment initiation, stratified by age, spanning two years from January 2019 until December 2020 from two large national labs (Quest and LabCorp). We performed segmented regression analysis by obtaining the estimated numbers of tests and treatments for each state from a mixed effects negative binomial model with Month as the main fixed predictor, and State as a random intercept. The predicted values from the model were aggregated by calculating the sum of the predicted number of tests or treatment initiations for each month and then aggregated values were regressed on month. Maximum likelihood estimation was used. Months from 1/2019 to 2/2020 (Months 1-14 in Figure) were designated the 'pre-COVID period' and 3/2020 to 12/2020 (Months 15-24) were designated the 'COVID period'. Results: During the pre-COVID period, the monthly number of HCV antibody tests in the US remained relatively stable with slight declines (p=0.712). Between February 2020 and March 2020, the predicted number of tests dropped significantly by 33% (p=0.004;similar trend in males and females and by state). During the COVID period through the end of 2020 (compared to the month-to-month trend before the COVID period) there was a significant increase in month-to-month testing (p=0.008;Figure 1). During the pre-COVID period, HCV treatment initiations were stable, but dropped significantly from March 2020 to April 2020 by 31% (p |
| تدمد: | 1527-3350 0270-9139 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::842284ddf36538b3e282be291a56ed45Test https://doi.org/10.1002/hep.32188Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........842284ddf36538b3e282be291a56ed45 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15273350 02709139 |
|---|